Compare Humana Inc (HUM) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs 22nd Century Group Inc — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while 22nd Century Group Inc trades at $4.46 (market cap $1.53M). The key difference: Humana Inc is far larger — about 30268× 22nd Century Group Inc's market cap, and Humana Inc pays a 0.92% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| HUM | XXII | |
|---|---|---|
Market Cap | $46.31B | $1.53M |
Sector | Health | Technology |
52-Week High | $409.42 | $801.00 |
52-Week Low | $163.67 | $3.72 |
Enterprise Value | $53.67B | -$6.70M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
22nd Century Group (XXII) trades at $4.29, down 0.69% with neutral technical signals. The company shows significant financial challenges with negative profit margins (-65.76% net income margin) and cash burn from operations (-$7.72M in 2025), though recent expansion into California and New York markets provides growth potential. Analyst sentiment remains positive with 75% buy ratings despite fundamental weaknesses.
The stock presents high-risk speculation with potential upside from market expansion and regulatory approvals, but requires careful monitoring of cash flow sustainability and path to profitability. Current valuation metrics (P/S 0.03, P/B 0.07) suggest discounted pricing relative to sales and assets, though profitability remains the critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
